GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (LTS:0TDD) » Definitions » Margin of Safety % (DCF FCF Based)

Novo Nordisk AS (LTS:0TDD) Margin of Safety % (DCF FCF Based) : -45.67% (As of Mar. 29, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Novo Nordisk AS Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2025-03-29), Novo Nordisk AS's Predictability Rank is 3-Stars. Novo Nordisk AS's intrinsic value calculated from the Discounted FCF model is $76.27 and current share price is $69.50. Consequently,

Novo Nordisk AS's Margin of Safety % (DCF FCF Based) using Discounted FCF model is -45.67%.

Competitive Comparison of Novo Nordisk AS's Margin of Safety % (DCF FCF Based)

For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novo Nordisk AS's Margin of Safety % (DCF FCF Based) Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Novo Nordisk AS's Margin of Safety % (DCF FCF Based) falls into.


;
;

Novo Nordisk AS Margin of Safety % (DCF FCF Based) Calculation

Novo Nordisk AS's Margin of Safety % (DCF FCF Based) for today is calculated as

Margin of Safety % (DCF FCF Based)=(Intrinsic Value: DCF (FCF Based)-Current Price)/Intrinsic Value: DCF (FCF Based)
=(47.71-69.50)/47.71
=-45.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted FCF model with default parameters. The calculation method is the same as Discounted Earnings model except free cash flow are used in the calculation instead of earnings per share.

Novo Nordisk AS Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Novo Nordisk AS's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Novo Nordisk AS (LTS:0TDD) » Definitions » Margin of Safety % (DCF FCF Based)
Comparable Companies
OCSE:HLUN A OCSE:STENO LLY JNJ ABBV XSWX:ROG LSE:AZN MRK XSWX:NOVN AMGN PFE GILD XPAR:SAN BMY TSE:4519 LSE:GSK TSE:4568 SHSE:600276 TSE:4578 XTER:BAYN
Traded in Other Exchanges
NONOF:USA NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany NVON:Canada N1VO34:Brazil NOV:Bulgaria NNO2:Austria
Address
Novo Alle 1, Bagsvaerd, DNK, 2880
Website
https://www.novonordisk.com
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Novo Nordisk AS Headlines

No Headlines